Maternal Glucose Levels Linked to Two CHD Phenotypes

This article originally appeared here.
Share this content:
Maternal Glucose Levels Linked to Two CHD Phenotypes
Maternal Glucose Levels Linked to Two CHD Phenotypes

TUESDAY, Oct. 13, 2015 (HealthDay News) -- Maternal midpregnancy measures of glucose and insulin are associated with two different congenital heart disease (CHD) phenotypes, according to a study published online Oct. 12 in JAMA Pediatrics.

James R. Priest, M.D., from the Stanford Cardiovascular Institute in California, and colleagues examined the potential correlation of two different CHD phenotypes in offspring with maternal midpregnancy measures of glucose and insulin. Data were included from 277 pregnant women carrying infants with tetralogy of Fallot (TOF; n = 55), infants with dextrotransposition of the great arteries (dTGA; n = 42), and healthy infants without CHD (n = 180).

The researchers found that maternal samples for offspring with TOF had elevated serum glucose values relative to controls (P = 0.01); this was not seen in maternal samples for offspring with dTGA relative to controls (P = 0.18). There was a significant difference between serum insulin levels in controls versus offspring with dTGA (P = 0.048) but not TOF (P = 0.35). In models including insulin, maternal blood glucose levels correlated strongly with odds of TOF (adjusted odds ratio, 7.54; 95 percent confidence interval, 2.3 to 24.69) but not dTGA (adjusted odds ratio, 1.16; 95 percent confidence interval, 0.28 to 4.79) relative to maternal blood glucose levels of infants without cardiac malformations.

"These results represent a direct correlation of glucose as a continuous variable to odds of specific cardiac malformations," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »